Hypertrophic cardiomyopathy

Progress in Cardiovascular Diseases

Volumn 36, Issue 4, 1994, Pages 275-308

  Louie, Eric K ^a   Edwards III, Lonnie C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DILTIAZEM; DISOPYRAMIDE; DIURETIC AGENT; MEXILETINE; NIFEDIPINE; QUINIDINE; THALLIUM 201; VERAPAMIL;

DEFIBRILLATION; DIAGNOSTIC IMAGING; DISEASE COURSE; DIURETIC THERAPY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; M MODE ECHOCARDIOGRAPHY; PATHOPHYSIOLOGY; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHY, HYPERTROPHIC; DIGITALIS GLYCOSIDES; DISOPYRAMIDE; DIURETICS; HUMAN; MYOCARDIUM; PACEMAKER, ARTIFICIAL; VENTRICULAR FUNCTION, LEFT;

EID: 0028078894     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-0620(05)80036-2     Document Type: Article

References (182)

1. Idiopathic hypertrophic subaortic stenosis: I. A description of the disease based upon an analysis of 64 patients
2. Hypertrophic cardiomyopathy, interrelations of clinical manifestations, pathophysiology, and therapy
3. Hypertrophic cardiomyopathy, interrelations of clinical manifestations, pathophysiology, and therapy
4. Asymmetric septal hypertrophy, echocardiographic identification of the pathognomonic anatomic abnormality of IHSS
5. Echocardiographic measurement of the left ventricular outflow gradient in idiopathic hypertrophic subaortic stenosis
6. Hypertrophic cardiomyopathy with unusual locations of left ventricular hypertrophy undetectable by M-mode echocardiography, identification by wide-angle two-dimensional echocardiography
7. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy
8. Hypertrophic cardiomyopathy: A discussion of nomenclature
9. A molecular basis for familial hypertrophic cardiomyopathy: An α/β cardiac myosin heavy chain hybrid gene
10. A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation
11. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A two-dimensional echocardiographic study
12. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review
13. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: Functional and morphologic features and clinical significance
14. Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy
15. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy
16. Midventricular obstruction A variant of obstructive cardiomyopathy
17. Hypertrophic cardiomyopathy characterized by marked hypertrophy of the posterior left ventricular free wall: Significance and clinical implications
18. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study
19. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): Ventriculographic and echocardiographic features in 30 patients
20. Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy)
21. Apical hypertrophic cardiomyopathy: Clinical and two-dimensional echocardiographic assessment
22. Apical hypertrophic cardiomyopathy: Evaluation by noninvasive and invasive techniques in 23 patients
23. Apical hypertrophic cardiomyopathy Clinical follow-up and diagnostic correlates
24. Prognosis in hypertrophic cardiomyopathy
25. Apical hypertrophic cardiomyopathy: A view from the U.S.A.
26. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy
27. Relation between extent of left ventricular hypertrophy and age in hypertrophic cardiomyopathy
28. Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy
29. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: Higher incidence in patients with midventricular obstruction
30. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilation in hypertrophic cardiomyopathy
31. Apical segmental dysfunction in hypertrophic cardiomyopathy: Subgroup with unique clinical features
32. Hypertensive hypertrophic cardiomyopathy
33. Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension?: A study of 78 patients
34. Elderly patients with hypertrophic cardiomyopathy: A subset with distinctive left ventricular morphology and progressive clinical course late in life
35. Hypertrophic cardiomyopathy in the elderly, distinctions from the young based on cardiac shape
36. Catenoid shape of the interventricular septum: Possible cause of idiopathic hypertrophic subaortic stenosis
37. The “sigmoid septum”: Variation in the contour of the left ventricular outlet
38. Natural history of hypertrophic cardiomyopathy in the elderly
39. Asymmetrical hypertrophy of the heart in young patients
40. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy
41. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy
42. Isometric cardiac contraction, a possible cause of the disorganized myocardial pattern of idiopathic hypertrophic subaortic stenosis
43. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy
44. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries
45. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts and hypertrophic cardiomyopathy
46. Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis
47. Prevalence of diagnostic abnormalities in patients with genetically transmitted asymmetric septal hypertrophy
48. Mode of inheritance of hypertrophic cardiomyopathy in Iceland
49. Patterns of inheritance in hypertrophic cardiomyopathy: Assessment by M-mode and two-dimensional echocardiography
50. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy, two-dimensional echocardiographic analysis
51. Familial spontaneous complete heart block in hypertrophic cardiomyopathy
52. Two forms of hypertrophic cardiomyopathy distinguished by inheritance of HLA haplotypes and left ventricular outflow tract obstruction
53. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1
54. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy, interaction between hemodynamic and thyroid hormone-induced signals
55. Molecular basis of cardiac performance, plasticity of the myocardium generated through protein isoform switches
56. Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy
57. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease
58. Risk, genotype, and cardiovascular disease
59. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy
60. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene
61. Forcevelocity-length relations in hypertrophic cardiomyopathy: Evidence of normal or depressed myocardial contractility
62. Hemodynamic technic for the detection of hypertrophic subaortic stenosis
63. Muscular subaortic stenosis: The direct relation between the intraventricular pressure difference and the left ventricular ejection time
64. Causal relation between the pressure gradient and left ventricular ejection time in hypertrophic cardiomyopathy
65. The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis
66. Pressure gradients without obstruction: A new concept of “hypertrophic subaortic stenosis”
67. Muscular subaortic stenosis. Initial left ventricular inflow tract pressure in the assessment of intraventricular pressure differences in man
68. Does outflow obstruction exist in hypertrophic cardiomyopathy?
69. Pressure-flow studies in hypertrophic subaortic stenosis
70. Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy
71. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: Analysis by pulsed Doppler echocardiography
72. Patterns and timing of Doppler detected intracavitary and aortic flow in hypertrophic cardiomyopathy
73. Hypertrophic obstructive cardiomyopathy, assessment by echocardiographic and Doppler ultrasound techniques
74. Variations in flow velocity waveforms obtained by pulsed Doppler echocardiography in the normal human aorta
75. Echocardiographic and Doppler assessment of hypertrophic cardiomyopathy
76. Hypertrophic cardiomyopathy: A 1987 viewpoint
77. Left ventricular ejection dynamics and outflow obstruction in hypertrophic cardiomyopathy
78. The challenge of cardiomyopathy
79. Significance of left ventricular outflow tract cross-sectional area in hypertrophic cardiomyopathy: A two-dimensional echocardiographic assessment
80. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis)
81. Pathophysiological consideration in muscular subaortic stenosis
82. Intraoperative Doppler echocardiography in hypertrophic cardiomyopathy: Correlations with the obstructive gradient
83. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy
84. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy
85. Pressure recovery distal to a stenosis: Potential cause of gradient “overestimation” by Doppler echocardiography
86. Systolic anterior motion of the posterior mitral leaflet: A previously unrecognized cause of dynamic subaortic obstruction in hypertrophic cardiomyopathy
87. Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: Assessment by two-dimensional echocardiography
88. Echocardiographic measurement of the left ventricular outflow gradient in idiopathic hypertrophic subaortic stenosis
89. Hypertrophic cardiomyopathy: Subclassification by M-mode echocardiography
90. Muscular subaortic stenosis: The temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient
91. Muscular subaortic stenosis: The quantitative relationship between systolic anterior motion and the pressure gradient
92. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations
93. Chordal geometry determines the shape and extent of systolic anterior mitral motion: In vitro studies
94. Two types of intraventricular pressure difference in the same patient. Left ventricular catheter entrapment and right ventricular outflow tract obstruction
95. Reversed Rivero-Carvallo's sign in right-sided hypertrophic obstructive cardiomyopathy
96. Obstruction within the right ventricular body: Two-dimensional echocardiographic features
97. Relation of left ventricular function and prognosis in hypertrophic cardiomyopathy: an angiographic study
98. Relation between marked changes in left ventricular outflow tract gradient and disease progression in hypertrophic cardiomyopathy
99. Hypertrophic cardiomyopathy: Is a left ventricular outflow tract gradient a major prognostic determinant?
100. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans
101. Combined influence of ventricular loading and relaxation on the transmitral flow velocity profile in dogs measured by Doppler echocardiography
102. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy
103. Left ventricular filling in hypertrophic cardiomyopathy, an angiographic study
104. Effects of nifedipine on left ventricular diastolic function in patients with asymptomatic or minimally symptomatic hypertrophic cardiomyopathy
105. Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis
106. Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: An echocardiographic study
107. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy
108. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: Effect of verapamil
109. Left ventricular filling in hypertrophic cardiomyopathy: A pulsed Doppler echocardiographic study
110. Left ventricular systolic and diastolic flow abnormalities determined by Doppler echocardiography in obstructive hypertrophic cardiomyopathy
111. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy
112. Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil
113. Determinants of exercise capacity in hypertrophic cardiomyopathy
114. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: Assessment with thallium 201 emission computed tomography
115. Myocardial ischemia in patients with hypertrophic cardiomyopathy: Contribution of inadequate vasodilator reserve and elevated left ventricular pressure
116. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy
117. Sudden cardiac death in hypetrophic cardiomyopathy
118. Sudden death in hypetrophic cardiomyopathy, assessment of patients at high risk
119. Sudden death in patients with hypertrophic cardiomyopathy: Characterization of 26 patients without functional limitation
120. Sudden death in hypertrophic cardiomyopathy: A profile of 78 patients
121. Hypertrophic cardiomyopathy: An important cause of sudden death
122. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest
123. Hemodynamic and electrophysiologic evaluation of patients with hypertrophic cardiomyopathy surviving cardiac arrest
124. Asymmetric septal hypertrophy in childhood
125. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy
126. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis
127. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study
128. Syncope in hypertrophic cardiomyopathy: Multivariate analysis of prognostic determinants
129. Arrhythmia and prognosis in infants, children, and adolescents with hypertrophic cardiomyopathy
130. Prognostic determinants in hypertrophic cardiomyopathy
131. Electrophysiologic abnormalities in patient with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients
132. Inductible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death
133. Signal averaged electrocardiography in hypertrophic cardiomyopathy
134. Hypertrophic cardiomyopathy and sudden death
135. Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study
136. Electrophysiologic findings in patients with idiopathic hypertrophic subaortic stenosis
137. Atrioventricular block and preexcitation in hypertrophic cardiomyopathy
138. Muscular subaortic stenosis associated with complete heart block
139. Complete heart block as a cause of syncope in asymmetric septal hypertrophy
140. Hypertrophic cardiomyopathy and complete heart block in infancy
141. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy
142. The clinical course in muscular subaortic stenosis, a retrospective and prospective study of 60 hemodynamically proved cases
143. Prognosis and mortality of hypertrophic obstructive cardiomyopathy
144. The natural and unnatural history of hypertrophic obstructive cardiomyopathy
145. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features
146. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population
147. Task Force III: Hypertrophic cardiomyopathy, other myopericardial diseases and mitral valve prolapse. Presented at the 16th Bethesda Conference: Cardiovascular Abnormalities in the Athlete: Recommendations Regarding Eligibility for Competition
148. Mural vegetations at the site of endocardial trauma in infective endocarditis complicating idiopathic hypertrophic subaortic stenosis
149. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis
150. Use of calcium channel blocking drugs in hypertrophic cardiomyopathy
151. Verapamil prevents silent myocardial perfusion abnormality during exercise in asymptomatic patients with hypertrophic cardiomyopathy
152. Treatment of hypertrophic obstructive cardiomyopathy with verapamil
153. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects
154. Verapamil therapy: A new approach to the pharmacologic treatment of hypetrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status
155. Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function
156. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy
157. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short and long term effects
158. Verapamil: Its potential for causing serious complications in patients with hypertrophic cardiomyopathy
159. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy
160. Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy
161. Improvement in left ventricular diastolic function during intravenous and oral diltiazem therapy in patients with hypertrophic cardiomyopathy: An echocardiographic study
162. Effects of diltiazem on left ventricular diastolic behavior in patients with hypertrophic cardiomyopathy: Evaluation with exercise pulsed Doppler echocardiography
163. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy, double blind crossover study
164. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration
165. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration
166. Arrhythmia in hypertrophic cardiomyopathy. II. Comparison of amiodarone and verapamil in treatment
167. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia
168. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy
169. Effects of long term treatment with amiodarone on exercise hemodynamics and left ventricular relaxation in patients with hypertrophic cardiomyopathy
170. Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone
171. Permanent pacing as treatment for hypertrophic cardiomyopathy
172. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy
173. Current operative treatment of hypertrophic cardiomyopathy
174. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis
175. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: A retrospective study
176. Laser myoplasty for hypertrophic cardiomyopathy In vitro experience in human post mortem hearts and in vivo experience in a canine model (transarterial) and human patient (intraoperative)
177. Morphologic determinants of hemodynamic state after ventricular septal myotomy-myectomy in patients with obstructive hypertrophic cardiomyopathy: M-mode and two-dimensional echocardiographic assessment
178. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy
179. Results of operation for coexistent obstructive hypertrophic cardiomyopathy and coronary artery disease
180. Aortic regurgitation: A common complication after surgery for hypertrophic obstructive cardiomyopathy
181. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy
182. Mitral valve replacement for idiopathic hypertrophic subaortic stenosis: Results in 27 patients